Prevention and control of seasonal influenza with vaccines: Recommendations of the Advisory Committee on Immunization Practices-United States, 2018-19 influenza season

MMWR Recommendations and Reports

Volumn 67, Issue 3, 2018, Pages

  Grohskopf, Lisa A ^a   Sokolow, Leslie Z ^a,b   Broder, Karen R ^c   Walter, Emmanuel B ^d   Fry, Alicia M ^a   Jernigan, Daniel B ^a  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^b BATTELLE MEMORIAL INSTITUTE   (United States)

^c NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE;

ADOLESCENT; ADULT; ADVISORY COMMITTEE; AGED; CHILD; FEMALE; HUMAN; IMMUNIZATION; INFANT; INFLUENZA; MALE; MIDDLE AGED; PRACTICE GUIDELINE; PREGNANCY; PRESCHOOL CHILD; PUBLIC HEALTH SERVICE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SEASON; UNITED STATES; YOUNG ADULT;

ADOLESCENT; ADULT; ADVISORY COMMITTEES; AGED; CENTERS FOR DISEASE CONTROL AND PREVENTION (U.S.); CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNIZATION SCHEDULE; INFANT; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; PREGNANCY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SEASONS; UNITED STATES; YOUNG ADULT;

EID: 85054846779     PISSN: 10575987     EISSN: 15458601     Source Type: Journal    
DOI: 10.15585/mmwr.rr6703a1     Document Type: Article

References (100)

1. Barker WH. Excess pneumonia and influenza associated hospitalization during influenza epidemics in the United States, 1970-78. Am J Public Health 1986;76:761-5. https://doi.org/10.2105/AJPH.76.7.761
2. Barker WH, Mullooly JP. Impact of epidemic type A influenza in a defined adult population. Am J Epidemiol 1980;112:798-813. https://doi.org/10.1093/oxfordjournals.aje.a113052
3. Poehling KA, Edwards KM, Griffin MR, et al. The burden of influenza in young children, 2004-2009. Pediatrics 2013;131:207-16. https://doi.org/10.1542/peds.2012-1255
4. Poehling KA, Edwards KM, Weinberg GA, et al.; New Vaccine Surveillance Network. The underrecognized burden of influenza in young children. N Engl J Med 2006;355:31-40. https://doi.org/10.1056/NEJMoa054869
5. Siston AM, Rasmussen SA, Honein MA, et al.; Pandemic H1N1 Influenza in Pregnancy Working Group. Pandemic 2009 influenza A(H1N1) virus illness among pregnant women in the United States. JAMA 2010;303:1517-25. https://doi.org/10.1001/jama.2010.479
6. Mullooly JP, Bridges CB, Thompson WW, et al.; Vaccine Safety Datalink Adult Working Group. Influenza-and RSV-associated hospitalizations among adults. Vaccine 2007;25:846-55. https://doi.org/10.1016/j.vaccine.2006.09.041
7. Fiore AE, Uyeki TM, Broder K, et al.; CDC. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep 2010;59(No. RR-8):1-62
8. Grohskopf LA, Sokolow LZ, Broder KR, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices-United States, 2017-18 influenza season. MMWR Recomm Rep 2017;66:(No. RR-2)1-20. https://doi.org/10.15585/mmwr.rr6602a1
9. Advisory Committee on Immunization Practices. Summary report: February 24, 2016 (Meeting minutes). Atlanta, GA: US Department of Health and Human Services, CDC; 2016
10. Des Roches A, Samaan K, Graham F, et al. Safe vaccination of patients with egg allergy by using live attenuated influenza vaccine. J Allergy Clin Immunol Pract 2015;3:138-9. https://doi.org/10.1016/j.jaip.2014.08.008
11. Turner PJ, Southern J, Andrews NJ, Miller E, Erlewyn-Lajeunesse M; SNIFFLE-2 Study Investigators. Safety of live attenuated influenza vaccine in young people with egg allergy: multicentre prospective cohort study. BMJ 2015;351:h6291. https://doi.org/10.1136/bmj.h6291
12. Turner PJ, Southern J, Andrews NJ, et al.; SNIFFLE Study Investigators. Safety of live attenuated influenza vaccine in atopic children with egg allergy. J Allergy Clin Immunol 2015;136:376-81. https://doi.org/10.1016/j.jaci.2014.12.1925
13. CDC. The flu season. Atlanta, GA: US Department of Health and Human Services, CDC; 2015. https://www.cdc.gov/flu/about/season/flu-season.htm
14. Castilla J, Martínez-Baz I, Martínez-Artola V, et al.; Primary Health Care Sentinel Network; Network for Influenza Surveillance in Hospitals of Navarre. Decline in influenza vaccine effectiveness with time after vaccination, Navarre, Spain, season 2011/12. Euro Surveill 2013;18:20388. https://doi.org/10.2807/ese.18.05.20388-en
15. Belongia EA, Sundaram ME, McClure DL, Meece JK, Ferdinands J, VanWormer JJ. Waning vaccine protection against influenza A (H3N2) illness in children and older adults during a single season. Vaccine 2015;33:246-51. https://doi.org/10.1016/j.vaccine.2014.06.052
16. Ferdinands JM, Fry AM, Reynolds S, et al. Intraseason waning of influenza vaccine protection: Evidence from the US Influenza Vaccine Effectiveness Network, 2011-12 through 2014-15. Clin Infect Dis 2017;64:544-50
17. Kissling E, Valenciano M, Larrauri A, et al. Low and decreasing vaccine effectiveness against influenza A(H3) in 2011/12 among vaccination target groups in Europe: results from the I-MOVE multicentre case-control study. Euro Surveill 2013;18:20390. https://doi.org/10.2807/ese.18.05.20390-en
18. Pebody R, Andrews N, McMenamin J, et al. Vaccine effectiveness of 2011/12 trivalent seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: evidence of waning intra-seasonal protection. Euro Surveill 2013;18:20389. https://doi.org/10.2807/ese.18.05.20389-en
19. Puig-Barberà J, Mira-Iglesias A, Tortajada-Girbés M, et al.; Valencia Hospital Network for the Study of Influenza and other Respiratory Viruses (VAHNSI, Spain). Waning protection of influenza vaccination during four influenza seasons, 2011/2012 to 2014/2015. Vaccine 2017;35:5799-807. https://doi.org/10.1016/j.vaccine.2017.09.035
20. Radin JM, Hawksworth AW, Myers CA, Ricketts MN, Hansen EA, Brice GT. Influenza vaccine effectiveness: maintained protection throughout the duration of influenza seasons 2010-2011 through 2013-2014. Vaccine 2016;34:3907-12. https://doi.org/10.1016/j.vaccine.2016.05.034
21. Kissling E, Nunes B, Robertson C, et al.; I-MOVE case-control study team. I-MOVE multicentre case-control study 2010/11 to 2014/15: is there within-season waning of influenza type/subtype vaccine effectiveness with increasing time since vaccination? Euro Surveill 2016;21
22. Petrie JG, Ohmit SE, Truscon R, et al. Modest waning of influenza vaccine efficacy and antibody titers during the 2007-2008 influenza season. J Infect Dis 2016;214:1142-9. https://doi.org/10.1093/infdis/jiw105
23. CDC. Immunization of health-care personnel: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011;60(No. RR-7):1-45
24. Pearson ML, Bridges CB, Harper SA; Healthcare Infection Control Practices Advisory Committee (HICPAC); Advisory Committee on Immunization Practices (ACIP). Influenza vaccination of health-care personnel: recommendations of the Healthcare Infection Control Practices Advisory Committee (HICPAC) and the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006;55(No. RR-2):1-16
25. Wright PF, Thompson J, Vaughn WK, Folland DS, Sell SH, Karzon DT. Trials of influenza A/New Jersey/76 virus vaccine in normal children: an overview of age-related antigenicity and reactogenicity. J Infect Dis 1977;136(Suppl 3):S731-41. https://doi.org/10.1093/infdis/136.Supplement_3.S731
26. Wright PF, Dolin R, La Montagne JR. Summary of clinical trials of influenza vaccines-II. J Infect Dis 1976;134:633-8. https://doi.org/10.1093/infdis/134.6.633
27. Wright PF, Sell SH, Thompson J, Karzon DT. Clinical reactions and serologic response following inactivated monovalent influenza type B vaccine in young children and infants. J Pediatr 1976;88:31-5. https://doi.org/10.1016/S0022-3476(76)80722-6
28. Gross PA. Reactogenicity and immunogenicity of bivalent influenza vaccine in one-and two-dose trials in children: a summary. J Infect Dis 1977;136(Suppl 3):S616-25. https://doi.org/10.1093/infdis/136.Supplement_3.S616
29. Bernstein DI, Zahradnik JM, DeAngelis CJ, Cherry JD. Clinical reactions and serologic responses after vaccination with whole-virus or split-virus influenza vaccines in children aged 6 to 36 months. Pediatrics 1982;69:404-8
30. Jain VK, Domachowske JB, Wang L, et al. Time to change dosing of inactivated quadrivalent influenza vaccine in young children: evidence from a Phase III, randomized, controlled trial. J Pediatric Infect Dis Soc 2017;6:9-19
31. Neuzil KM, Jackson LA, Nelson J, et al. Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccine-naive 5-8-year-old children. J Infect Dis 2006;194:1032-9. https://doi.org/10.1086/507309
32. Allison MA, Daley MF, Crane LA, et al. Influenza vaccine effectiveness in healthy 6-to 21-month-old children during the 2003-2004 season. J Pediatr 2006;149:755-62. https://doi.org/10.1016/j.jpeds.2006.06.036
33. Ritzwoller DP, Bridges CB, Shetterly S, Yamasaki K, Kolczak M, France EK. Effectiveness of the 2003-2004 influenza vaccine among children 6 months to 8 years of age, with 1 vs 2 doses. Pediatrics 2005;116:153-9. https://doi.org/10.1542/peds.2005-0049
34. Eisenberg KW, Szilagyi PG, Fairbrother G, et al.; New Vaccine Surveillance Network. Vaccine effectiveness against laboratory-confirmed influenza in children 6 to 59 months of age during the 2003-2004 and 2004-2005 influenza seasons. Pediatrics 2008;122:911-9. https://doi.org/10.1542/peds.2007-3304
35. ACOG Committee on Obstetric Practice. ACOG Committee Opinion No. 732. Influenza vaccination during pregnancy. Obstet Gynecol 2018;131:e109-14. https://doi.org/10.1097/AOG.0000000000002588
36. ACOG Committee on Obstetric Practice. ACOG Committee Opinion No. 732. Mummary: influenza vaccination during pregnancy. Obstet Gynecol 2018;131:752-3. https://doi.org/10.1097/AOG.0000000000002586
37. ACOG Immunization, Infectious Disease, and Public Health Preparedness Expert Work Group. ACOG Committee Opinion No. 741. Maternal immunization. Obstet Gynecol 2018;131:e214-7. https://doi.org/10.1097/AOG.0000000000002665
38. Donahue JG, Kieke BA, King JP, et al. Association of spontaneous abortion with receipt of inactivated influenza vaccine containing H1N1pdm09 in 2010-11 and 2011-12. Vaccine 2017;35:5314-22. https://doi.org/10.1016/j.vaccine.2017.06.069
39. Chambers CD, Johnson DL, Xu R, et al.; OTIS Collaborative Research Group. Safety of the 2010-11, 2011-12, 2012-13, and 2013-14 seasonal influenza vaccines in pregnancy: birth defects, spontaneous abortion, preterm delivery, and small for gestational age infants, a study from the cohort arm of VAMPSS. Vaccine 2016;34:4443-9. https://doi.org/10.1016/j.vaccine.2016.06.054
40. Huang WT, Tang FW, Yang SE, Chih YC, Chuang JH. Safety of inactivated monovalent pandemic (H1N1) 2009 vaccination during pregnancy: a population-based study in Taiwan. Vaccine 2014;32:6463-8. https://doi.org/10.1016/j.vaccine.2014.09.054
41. Ma F, Zhang L, Jiang R, et al. Prospective cohort study of the safety of an influenza A(H1N1) vaccine in pregnant Chinese women. Clin Vaccine Immunol 2014;21:1282-7. https://doi.org/10.1128/CVI.00375-14
42. Irving SA, Kieke BA, Donahue JG, et al.; Vaccine Safety Datalink. Trivalent inactivated influenza vaccine and spontaneous abortion. Obstet Gynecol 2013;121:159-65. https://doi.org/10.1097/AOG.0b013e318279f56f
43. Chambers CD, Johnson D, Xu R, et al. Risks and safety of pandemic H1N1 influenza vaccine in pregnancy: birth defects, spontaneous abortion, preterm delivery, and small for gestational age infants. Vaccine 2013;31:5026-32
44. Oppermann M, Fritzsche J, Weber-Schoendorfer C, et al. A(H1N1)v2009: a controlled observational prospective cohort study on vaccine safety in pregnancy. Vaccine 2012;30:4445-52. https://doi.org/10.1016/j.vaccine.2012.04.081
45. Pasternak B, Svanström H, Mølgaard-Nielsen D, et al. Vaccination against pandemic A/H1N1 2009 influenza in pregnancy and risk of fetal death: cohort study in Denmark. BMJ 2012;344:e2794. https://doi.org/10.1136/bmj.e2794
46. Sammon CJ, Snowball J, McGrogan A, de Vries CS. Evaluating the hazard of foetal death following H1N1 influenza vaccination; a population based cohort study in the UK GPRD. PLoS One 2012;7:e51734. https://doi.org/10.1371/journal.pone.0051734
47. Heikkinen T, Young J, van Beek E, et al. Safety of MF59-adjuvanted A/H1N1 influenza vaccine in pregnancy: a comparative cohort study. Am J Obstet Gynecol 2012;207:177 e1-8
48. McMillan M, Porritt K, Kralik D, Costi L, Marshall H. Influenza vaccination during pregnancy: a systematic review of fetal death, spontaneous abortion, and congenital malformation safety outcomes. Vaccine 2015;33:2108-17. https://doi.org/10.1016/j.vaccine.2015.02.068
49. Bratton KN, Wardle MT, Orenstein WA, Omer SB. Maternal influenza immunization and birth outcomes of stillbirth and spontaneous abortion: a systematic review and meta-analysis. Clin Infect Dis 2015;60:e11-9. https://doi.org/10.1093/cid/ciu915
50. Advisory Committee on Immunization Practices. Summary report: October 25-26, 2017 (Meeting minutes). Atlanta, GA: US Department of Health and Human Services, CDC; 2017
51. FluLaval Quadrivalent [Package Insert]. Quebec City, Quebec, Canada: ID Biomedical Corporation of Quebec; 2018
52. Fluarix Quadrivalent [Package Insert]. Research Triangle Park, North Carolina: GlaxoSmithKline; 2018
53. Afluria Quadrivalent [Package Insert]. Parkville, Victoria, Australia: Seqirus; 2018
54. Flucelvax Quadrivalent [Package Insert]. Holly Springs, NC: Seqirus; 2018
55. Flublok Quadrivalent [Package Insert]. Swiftwater, PA: Sanofi Pasteur; 2018
56. Fluzone Quadrivalent. Swiftwater, PA: Sanofi Pasteur; 2018
57. DiazGranados CA, Dunning AJ, Kimmel M, et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med 2014;371:635-45. https://doi.org/10.1056/NEJMoa1315727
58. DiazGranados CA, Robertson CA, Talbot HK, Landolfi V, Dunning AJ, Greenberg DP. Prevention of serious events in adults 65 years of age or older: a comparison between high-dose and standard-dose inactivated influenza vaccines. Vaccine 2015;33:4988-93. https://doi.org/10.1016/j.vaccine.2015.07.006
59. Dunkle LM, Izikson R, Patriarca P, et al.; PSC12 Study Team. Efficacy of recombinant influenza vaccine in adults 50 years of age or older. N Engl J Med 2017;376:2427-36. https://doi.org/10.1056/NEJMoa1608862
60. Van Buynder PG, Konrad S, Van Buynder JL, et al. The comparative effectiveness of adjuvanted and unadjuvanted trivalent inactivated influenza vaccine (TIV) in the elderly. Vaccine 2013;31:6122-8. https://doi.org/10.1016/j.vaccine.2013.07.059
61. Clinical Review: Fluad. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2014
62. Falsey AR, Treanor JJ, Tornieporth N, Capellan J, Gorse GJ. Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. J Infect Dis 2009;200:172-80. https://doi.org/10.1086/599790
63. Fluzone High-Dose [Package Insert]. Swiftwater, PA: Sanofi Pasetur; 2018
64. Food and Drug Administration. October 29, 2014 clinical review-Fluzone High-Dose. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2014
65. Gravenstein S, Davidson HE, Taljaard M, et al. Comparative effectiveness of high-dose versus standard-dose influenza vaccination on numbers of US nursing home residents admitted to hospital: a cluster-randomised trial. Lancet Respir Med 2017;5:738-46. https://doi.org/10.1016/S2213-2600(17)30235-7
66. Young-Xu Y, Van Aalst R, Mahmud SM, et al. Relative vaccine effectiveness of high-dose versus standard-dose influenza vaccines among Veterans Health Administration patients. J Infect Dis 2018;217:1718-27. https://doi.org/10.1093/infdis/jiy088
67. Richardson DM, Medvedeva EL, Roberts CB, Linkin DR; CDC Epicenter Program. Comparative effectiveness of high-dose versus standard-dose influenza vaccination in community-dwelling veterans. Clin Infect Dis 2015;61:171-6. https://doi.org/10.1093/cid/civ261
68. Shay DK, Chillarige Y, Kelman J, et al. Comparative effectiveness of high-dose versus standard-dose influenza vaccines among US Medicare beneficiaries in preventing postinfluenza deaths during 2012-2013 and 2013-2014. J Infect Dis 2017;215:510-7. https://doi.org/10.1093/infdis/jiw641
69. Izurieta HS, Thadani N, Shay DK, et al. Comparative effectiveness of high-dose versus standard-dose influenza vaccines in US residents aged 65 years and older from 2012 to 2013 using Medicare data: a retrospective cohort analysis. Lancet Infect Dis 2015;15:293-300. https://doi.org/10.1016/S1473-3099(14)71087-4
70. Lee JKH, Lam GKL, Shin T, et al. Efficacy and effectiveness of high-dose versus standard-dose influenza vaccination for older adults: a systematic review and meta-analysis. Expert Rev Vaccines 2018;17:435-43
71. Food and Drug Administration. Summary basis for regulatory action-Flublok Quadrivalent. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2016
72. Kroger AT, Duchin J, Vázquez M. Best practices guidance of the Advisory Committee on Immunization Practices (ACIP). Atlanta, GA: US Department of Health and Human Services, CDC; 2017. https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf
73. Rubin LG, Levin MJ, Ljungman P, et al.; Infectious Diseases Society of America. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 2014;58:e44-100. https://doi.org/10.1093/cid/cit684
74. CDC. Antiviral drugs: information for healthcare professionals. Atlanta, GA: US Department of Health and Human Services, CDC. https://www.cdc.gov/flu/professionals/antivirals/index.htm
75. Erlewyn-Lajeunesse M, Brathwaite N, Lucas JS, Warner JO. Recommendations for the administration of influenza vaccine in children allergic to egg. BMJ 2009;339(sep15 3):b3680. https://doi.org/10.1136/bmj.b3680
76. CDC. Advisory Committee on Immunization Practices summary report: June 20-21, 2012 (meeting minutes). Atlanta, GA: US Department of Health and Human Services, CDC; 2012
77. CDC. Advisory Committee on Immunization Practices summary report: June 19-20, 2013 (meeting minutes). Atlanta, GA: US Department of Health and Human Services, CDC; 2013
78. Miller JM, Tam TW, Maloney S, et al. Cruise ships: high-risk passengers and the global spread of new influenza viruses. Clin Infect Dis 2000;31:433-8. https://doi.org/10.1086/313974
79. Uyeki TM, Zane SB, Bodnar UR, et al.; Alaska/Yukon Territory Respiratory Outbreak Investigation Team. Large summertime influenza A outbreak among tourists in Alaska and the Yukon Territory. Clin Infect Dis 2003;36:1095-102. https://doi.org/10.1086/374053
80. Mutsch M, Tavernini M, Marx A, et al. Influenza virus infection in travelers to tropical and subtropical countries. Clin Infect Dis 2005;40:1282-7. https://doi.org/10.1086/429243
81. Ratnam I, Black J, Leder K, et al. Incidence and risk factors for acute respiratory illnesses and influenza virus infections in Australian travellers to Asia. J Clin Virol 2013;57:54-8. https://doi.org/10.1016/j.jcv.2013.01.008
82. Flumist Quadrivalent [Package Insert]. Gaithersburg, Maryland: MedImmune; 2018
83. Kerzner B, Murray AV, Cheng E, et al. Safety and immunogenicity profile of the concomitant administration of ZOSTAVAX and inactivated influenza vaccine in adults aged 50 and older. J Am Geriatr Soc 2007;55:1499-507. https://doi.org/10.1111/j.1532-5415.2007.01397.x
84. Frenck RW Jr, Gurtman A, Rubino J, et al. Randomized, controlled trial of a 13-valent pneumococcal conjugate vaccine administered concomitantly with an influenza vaccine in healthy adults. Clin Vaccine Immunol 2012;19:1296-303. https://doi.org/10.1128/CVI.00176-12
85. Schwarz TF, Flamaing J, Rümke HC, et al. A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged =65 years. Vaccine 2011;29:5195-202. https://doi.org/10.1016/j.vaccine.2011.05.031
86. McNeil SA, Noya F, Dionne M, et al. Comparison of the safety and immunogenicity of concomitant and sequential administration of an adult formulation tetanus and diphtheria toxoids adsorbed combined with acellular pertussis (Tdap) vaccine and trivalent inactivated influenza vaccine in adults. Vaccine 2007;25:3464-74. https://doi.org/10.1016/j.vaccine.2006.12.047
87. Song JY, Cheong HJ, Tsai TF, et al. Immunogenicity and safety of concomitant MF59-adjuvanted influenza vaccine and 23-valent pneumococcal polysaccharide vaccine administration in older adults. Vaccine 2015;33:4647-52. https://doi.org/10.1016/j.vaccine.2015.05.003
88. Sukumaran L, McCarthy NL, Kharbanda EO, et al. Safety of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis and influenza vaccinations in pregnancy. Obstet Gynecol 2015;126:1069-74. https://doi.org/10.1097/AOG.0000000000001066
89. Stockwell MS, Broder K, LaRussa P, et al. Risk of fever after pediatric trivalent inactivated influenza vaccine and 13-valent pneumococcal conjugate vaccine. JAMA Pediatr 2014;168:211-9. https://doi.org/10.1001/jamapediatrics.2013.4469
90. Duffy J, Weintraub E, Hambidge SJ, et al.; Vaccine Safety Datalink. Febrile seizure risk after vaccination in children 6 to 23 months. Pediatrics 2016;138:e20160320. https://doi.org/10.1542/peds.2016-0320
91. Li R, Stewart B, McNeil MM, et al. Post licensure surveillance of influenza vaccines in the Vaccine Safety Datalink in the 2013-2014 and 2014-2015 seasons. Pharmacoepidemiol Drug Saf 2016;25:928-34. https://doi.org/10.1002/pds.3996
92. Patterson JL, Carapetian SA, Hageman JR, Kelley KR. Febrile seizures. Pediatr Ann 2013;42:e258-63. https://doi.org/10.3928/00904481-20131122-09
93. Nolan T, Bernstein DI, Block SL, et al.; LAIV Study Group. Safety and immunogenicity of concurrent administration of live attenuated influenza vaccine with measles-mumps-rubella and varicella vaccines to infants 12 to 15 months of age. Pediatrics 2008;121:508-16. https://doi.org/10.1542/peds.2007-1064
94. Lum LC, Borja-Tabora CF, Breiman RF, et al. Influenza vaccine concurrently administered with a combination measles, mumps, and rubella vaccine to young children. Vaccine 2010;28:1566-74. https://doi.org/10.1016/j.vaccine.2009.11.054
95. Schwarz TF, Aggarwal N, Moeckesch B, et al. Immunogenicity and safety of an adjuvanted herpes zoster subunit vaccine coadministered with aged seasonal influenza vaccine in adults 50 years or older. J Infect Dis 2017;216:1352-61. https://doi.org/10.1093/infdis/jix481
96. Afluria [Package Insert]. Parkville, Victoria, Australia: Seqirus; 2018
97. Airey J, Albano FR, Sawlwin DC, et al. Immunogenicity and safety of a quadrivalent inactivated influenza virus vaccine compared with a comparator quadrivalent inactivated influenza vaccine in a pediatric population: A phase 3, randomized noninferiority study. Vaccine 2017;35:2745-52
98. Clinical Review. (STN: 125127/834)-Fluarix Quadrivalent. Sliver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2018. https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM593001.pdf
99. Claeys C, Zaman K, Dbaibo G, et al. Prevention of vaccine-matched and mismatched influenza in children aged 6-35 months: a multinational randomized trial across five influenza seasons. Lancet Child Adolesc Health 2018;2:338-49
100. Health Resources and Services Administration. What you need to know about the National Vaccine Injury Compensation Program (VICP). Washington, DC: US Department of Health and Human Services, Health Resources and Services Administration; 2016